Gastrointestinal Stromal Tumors. Risk Assessment and Adjuvant Therapy.

Hematology/Oncology Clinics of North America

Volumn 27, Issue 5, 2013, Pages 889-904

  Joensuu, Heikki ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Adjuvant therapy; Gastrointestinal stromal tumor; Imatinib; Prognostic factor; Risk stratification

Indexed keywords

AURORA A KINASE; IMATINIB; PLACEBO; PLATELET DERIVED GROWTH FACTOR A; SUCCINATE DEHYDROGENASE; SUNITINIB;

ABDOMEN; ANEMIA; ANEUPLOIDY; AREA UNDER THE CURVE; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; COMPARATIVE GENOMIC HYBRIDIZATION; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DISTANT METASTASIS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; EARLY DIAGNOSIS; EPIPHORA; FATIGUE; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; HIGH RISK PATIENT; HUMAN; IONIZING RADIATION; LATENT PERIOD; LONGITUDINAL STUDY; LYMPH NODE METASTASIS; METASTASIS FREE SURVIVAL; MITOSIS; MITOSIS RATE; MUSCLE CRAMP; NAUSEA; NOMOGRAM; OPTIMAL DRUG DOSE; OVERALL SURVIVAL; PELVIS; PERIORBITAL EDEMA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEIVER OPERATING CHARACTERISTIC; RECURRENCE FREE SURVIVAL; REVIEW; RISK ASSESSMENT; TOTAL STOMACH RESECTION; TREATMENT DURATION; TUMOR GROWTH; TUMOR RECURRENCE; TUMOR VOLUME; ADJUVANT THERAPY; CLINICAL TRIAL (TOPIC); GASTROINTESTINAL TUMOR; MULTIMODALITY CANCER THERAPY; PROGNOSIS; PROGNOSTIC FACTOR; RECURRENT DISEASE; RISK STRATIFICATION;

ADJUVANT THERAPY; GASTROINTESTINAL STROMAL TUMOR; IMATINIB; PROGNOSTIC FACTOR; RISK STRATIFICATION;

CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; FOLLOW-UP STUDIES; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; PROGNOSIS; RECURRENCE; RISK ASSESSMENT;

EID: 84884989340     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2013.07.004     Document Type: Review

References (74)

1. Emile J.F., Brahini S., Coindre J.M., et al. Frequencies of KIT and PDGFRA mutations in the MolecGIST prospective population-based study differ from those of advanced GISTs. Med Oncol 2012, 29(3):1765-1772.
2. Woodall C.E., Brock G.N., Fan J., et al. An evaluation of 2537 gastrointestinal stromal tumors for a proposed clinical staging system. Arch Surg 2009, 144(7):670-678.
3. Joensuu H., Vehtari A., Riihimäki J., et al. Risk of gastrointestinal stromal tumour recurrence after surgery: an analysis based on pooled population-based cohorts. Lancet Oncol 2012, 13(3):265-274.
4. DeMatteo R.P., Lewis J.J., Leung D., et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000, 231(1):51-58.
5. Demetri G.D., von Mehren M., Blanke C.D., et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. NEngl J Med 2002, 347(7):472-480.
6. Verweij J., Casali P.G., Zalcberg J., et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004, 364(9440):1127-1134.
7. Blanke C.D., Demetri G.D., von Mehren M., et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. JClin Oncol 2008, 26(4):620-625.
8. Von Mehren M. Follow-up results after 9 years of the ongoing, phase II B2222 trial of imatinib mesylate in patients with metastatic or unresectable KIT+ gastrointestinal stromal tumors (GIST). JClin Oncol 2011, 29(Suppl):609s.
9. Buchdunger E., Cioffi C.L., Law N., et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits invitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. JPharmacol Exp Ther 2000, 295(1):139-145.
10. DeMatteo R.P., Ballman K.V., Antonescu C.R., et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 2009, 373(9669):1097-1104.
11. Joensuu H., Eriksson M., Sundby Hall K., et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA 2012, 307(12):1265-1272.
12. Reichardt P., Hartmann J., Sundby Hall K., et al. Response to imatinib rechallenge of GIST that recurs following completion of adjuvant imatinib treatment-the first analysis in the SSGXVIII/AIO trial patient population. Eur J Cancer 2011, 47(Suppl 2):15.
13. Miettinen M., Sobin L.H., Lasota J. Gastrointestinal stromal tumors of the stomach. A clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol 2005, 29(1):52-68.
14. Miettinen M., Makhlouf H., Sobin L.H., et al. Gastrointestinal stromal tumors of the jejunum and ileum. A clinopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term-follow-up. Am J Surg Pathol 2006, 30(4):477-489.
15. DeMatteo R.P., Gold J.S., Saran L., et al. Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer 2008, 112(3):608-615.
16. Crosby J.A., Catton C.N., Davis A., et al. Malignant gastrointestinal stromal tumors of the small intestine: a review of 50 cases from a prospective database. Ann Surg Oncol 2001, 8(1):50-59.
17. Gal R., Rath-Wolfson L., Rosenblatt Y., et al. An improved technique for mitosis counting. Int J Surg Pathol 2005, 13(2):161-165.
18. Jiang J., Jin M.S., Suo J., et al. Evaluation of malignancy using Ki-67, p53, EGFR and COX-2 expressions in gastrointestinal stromal tumors. World J Gastroenterol 2012, 18(20):2569-2575.
19. Liang Y.M., Li X.H., Li W.M., et al. Prognostic significance of PTEN, Ki-67 and CD44s expression patterns in gastrointestinal stromal tumors. World J Gastroenterol 2012, 18(14):1664-1671.
20. Miettinen M., Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 2006, 23(2):70-83.
21. Gold J.S., Gönen M., Gutiérrez A., et al. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol 2009, 10(11):1045-1052.
22. Rossi S., Miceli R., Messerini L., et al. Natural history of imatinib-naive GISTs: a retrospective analysis of 929 cases with long-term follow-up and development of a survival nomogram based on mitotic index and size as continuous variables. Am J Surg Pathol 2011, 35(11):1646-1656.
23. Rutkowski P., Bylina E., Wozniak A., et al. Validation of the Joensuu risk criteria for primary resectable gastrointestinal stromal tumour-the impact of tumour rupture on patient outcomes. Eur J Surg Oncol 2011, 37(10):890-896.
24. Miettinen M., Furlong M., Sarlomo-Rikala M., et al. Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the rectum and anus: a clinicopathologic, immunohistochemical, and molecular genetic study of 144 cases. Am J Surg Pathol 2001, 25(9):1121-1133.
25. Takahashi T., Nakajima K., Nishitani A., et al. An enhanced risk-group stratification system for more practical prognostication of clinically malignant gastrointestinal stromal tumors. Int J Clin Oncol 2007, 12(5):369-374.
26. Hohenberger P., Ronellenfitsch U., Oladeji O., et al. Pattern of recurrence in patients with ruptured primary gastrointestinal stromal tumour. Br J Surg 2010, 97(12):1854-1859.
27. Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol 2008, 39(10):1411-1419.
28. Fletcher C.D., Berman J.J., Corless C., et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002, 33(5):459-465.
29. Miettinen M., Kopczynski J., Makhlouf H.R., et al. Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the duodenum: a clinicopathologic, immunohistochemical, and molecular genetic study of 167 cases. Am J Surg Pathol 2003, 27(5):625-641.
30. Agaimy A., Wünsch P.H. Lymph node metastasis in gastrointestinal stromal tumours (GIST) occurs preferentially in young patients < or= 40 years: an overview based on our case material and the literature. Langenbecks Arch Surg 2009, 394:375-381.
31. Zhang L., Smyrk T.C., Young W.F., et al. Gastric stromal tumors in Carney triad are different clinically, pathologically, and behaviorally from sporadic gastric gastrointestinal stromal tumors: findings in 104 cases. Am J Surg Pathol 2010, 34:53-64.
32. Rege T.A., Wagner A.J., Corless C.L., et al. "Pediatric-type" gastrointestinal stromal tumors in adults: distinctive histology predicts genotype and clinical behavior. Am J Surg Pathol 2011, 35:495-504.
33. Lagarde P., Pérot G., Kauffmann A., et al. Mitotic checkpoints and chromosome instability are strong predictors of clinical outcome in gastrointestinal stromal tumors. Clin Cancer Res 2012, 18(3):826-838.
34. Zhou H., Kuang J., Zhong L., et al. Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat Genet 1998, 20(2):189-193.
35. Yen C.C., Yeh C.N., Cheng C.T., et al. Integrating bioinformatics and clinicopathological research of gastrointestinal stromal tumors: identification of aurora kinase A as a poor risk marker. Ann Surg Oncol 2012, 19(11):3491-3499.
36. Bertucci F., Finetti P., Ostrowski J., et al. Genomic Grade Index predicts postoperative clinical outcome of GIST. Br J Cancer 2012, 107(8):1433-1441.
37. Sotiriou C., Wirapati P., Loi S., et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. JNatl Cancer Inst 2006, 98(4):262-272.
38. National Comprehensive Cancer Network. Clinical practice guidelines in oncology. Soft tissue sarcoma. V. 2.2011. Available at: Accessed January 31, 2013. http://www.nccn.org/professionals/physician_gls/.
39. ESMO/European Sarcoma Network Working Group Gastrointestinal stromal tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012, 23(Suppl 7):vii49-vii55.
40. Casali P. Imatinib failure-free survival in patients with localized gastrointestinal stromal tumors (GIST) treated with adjuvant imatinib: The EORTC/AGITG/FSG/GEIS/ISG randomized controlled phase III trial. JClin Oncol 2013, 31(Suppl):632s.
41. Joensuu H., Trent J.C., Reichardt P. Practical management of tyrosine-kinase inhibitor-associated side effects in GIST. Cancer Treat Rev 2011, 37(1):75-88.
42. DeMatteo RP, Owzar K, Antonescu CR, etal. Efficacy of adjuvant imatinib mesylate following complete resection of localized, primary gastrointestinal stromal tumor (GIST) at high risk of recurrence: the U.S. Intergroup phase II trial ACOSOG Z9000. Presented at American Society of Clinical Oncology 2008 Gastrointestinal Cancers Symposium. Orlando, January 25-27, 2008 [abstract 8].
43. Kanda T., Nishida T., Wada N., et al. Adjuvant therapy with imatinib mesylate after resection of primary high-risk gastrointestinal stromal tumors in Japanese patients. Int J Clin Oncol 2013, 18(1):38-45.
44. Kang B., Lee J., Ryu M., et al. Aphase II study of imatinib mesylate as adjuvant treatment for curatively resected high-risk localized gastrointestinal stromal tumors. JClin Oncol 2009, 27(Suppl):e21515.
45. Zhan W.H. Efficacy and safety of adjuvant post-surgical therapy with imatinib in patients with high risk of relapsing GIST. JClin Oncol 2007, 25(Suppl):556s.
46. Nilsson B., Sjölund K., Kindblom L.G., et al. Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST). Br J Cancer 2007, 96(11):1656-1658.
47. Huang H., Liang H., Zhan Z.L., et al. Surgical outcomes of gastrointestinal stromal tumors of the stomach: a single unit experience in the era of targeted drug therapy. Med Oncol 2012, 29(2):941-947.
48. Jiang W.Z., Guan G.X., Lu H.S., et al. Adjuvant imatinib treatment after R0 resection for patients with high-risk gastrointestinal stromal tumors: a median follow-up of 44 months. JSurg Oncol 2011, 104(7):760-764.
49. Li J., Gong J.F., Wu A.W., et al. Post-operative imatinib in patients with intermediate or high risk gastrointestinal stromal tumor. Eur J Surg Oncol 2011, 37(10):319-324.
50. Wang D., Zhang Q., Blanke C.D., et al. Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132. Ann Surg Oncol 2012, 19(4):1074-1080.
51. Andtbacka R.H., Ng C.S., Scaife C.L., et al. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Ann Surg Oncol 2007, 14(1):14-24.
52. McAuliffe J.C., Hunt K.K., Lazar J.F., et al. Arandomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis. Ann Surg Oncol 2009, 16(4):910-919.
53. Hohenberger P., Oladeji O., Licht T., et al. Neoadjuvant imatinib and organ preservation in locally advanced gastrointestinal stromal tumors (GIST). JClin Oncol 2009, 27(Suppl):548s.
54. Blesius A., Cassier P.A., Bertucci F., et al. Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BRF 14 trial. BMC Cancer 2011, 11:72.
55. Eisenberg B.L., Trent J.C. Adjuvant and neoadjuvant imatinib therapy: current role in the management of gastrointestinal stromal tumors. Int J Cancer 2011, 129(11):2533-2542.
56. Wardelmann E., Losen I., Hans V., et al. Deletion of Trp-557 and Lys-558 in the juxtamembrane domain of the c-kit protooncogene is associated with metastatic behavior of gastrointestinal stromal tumors. Int J Cancer 2003, 106(6):887-895.
57. Martin J., Poveda A., Llombart-Bosch A., et al. Deletions affecting codons 557-558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS). JClin Oncol 2005, 23(25):6190-6198.
58. Corless C.L., Schroeder A., Griffith D., et al. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and invitro sensitivity to imatinib. JClin Oncol 2005, 23(23):5357-5364.
59. Weisberg E., Wright R.D., Jiang J., et al. Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity. Gastroenterology 2006, 131(6):1734-1742.
60. Cassier P.A., Fumagilli E., Rutkowski P., et al. Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era. Clin Cancer Res 2012, 18(16):4458-4464.
61. Heinrich M.C., Griffith D., McKinley A., et al. Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors. Clin Cancer Res 2012, 18(16):4375-4384.
62. Corless C., Ballman K.V., Antonescu C., et al. Relation of tumor pathologic and molecular features to outcome after surgical resection of localized primary gastrointestinal stromal tumor (GIST): results of the intergroup phase III trial ACOSOG Z9001. JClin Oncol 2010, 28(Suppl):699s.
63. Miettinen M., Fetsch J.F., Sobin L.H., et al. Gastrointestinal stromal tumors in patients with neurofibromatosis 1: a clinicopathologic and molecular genetic study of 45 cases. Am J Surg Pathol 2006, 30(1):90-96.
64. Mussi C., Schildhaus H.U., Gronchi A., et al. Therapeutic consequences from molecular biology for gastrointestinal stromal tumor patients affected by neurofibromatosis type 1. Clin Cancer Res 2008, 14(14):4550-4555.
65. Debiec-Rychter M., Sciot R., Le Cesne A., et al. EORTC Soft Tissue and Bone Sarcoma Group; Italian Sarcoma Group; Australasian GastroIntestinal Trials Group. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006, 42(8):1093-1103.
66. Demetri G.D., Wang Y., Wehrle E., et al. Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. JClin Oncol 2009, 27(19):3141-3147.
67. Eechoute K., Fransson M.N., Reyners A.K., et al. Along-term prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patients. Clin Cancer Res 2012, 18(20):5780-5787.
68. Yoo C., Ryu M.H., Kang B.W., et al. Cross-sectional study of imatinib plasma trough levels in patients with advanced gastrointestinal stromal tumors: impact of gastrointestinal resection on exposure to imatinib. JClin Oncol 2010, 28(9):1554-1559.
69. Judson I.R. Therapeutic drug monitoring of imatinib-new data strengthen the case. Clin Cancer Res 2012, 18(20):517-519.
70. Blesius A. Who are the long responders to imatinib in patients with advanced GIST? Results of the BRF14 prospective French Sarcoma Group randomized phase III trial. JClin Oncol 2011, 29(Suppl):616s.
71. Davies H.E., Wathen C.G., Gleeson F.V. The risks of radiation exposure related to diagnostic imaging and how to minimise them. BMJ 2011, 342:d947.
72. ClinicalTrials.gov. Available at: Accessed January 31, 2013. http://www.clinicaltrials.gov/.
73. ISRCTN register. Available at: Accessed January 31, 2013. http://isrctn.org/.
74. Bardsley M.R., Horváth V.J., Asuzu D.T., et al. Kitlow stem cells cause resistance to Kit/platelet-derived growth factor alpha inhibitors in murine gastrointestinal stromal tumors. Gastroenterology 2010, 139(3):942-952.